Tevogen Bio Holdings(TVGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TVGN Tevogen Bio Holdings

Market Closed 05-29 16:00:00 EDT

7.91

-0.13

-1.62%

盘后7.91

+0.000.00%

17:41 EDT

High8.04	Low7.50	Vol25.77K
Open7.51	D1 Closing8.04	Amplitude6.74%
Mkt Cap32.94M	Tradable Cap8.96M	Total Shares4.16M
T/O199.12K	T/O Rate2.27%	Tradable Shares1.13M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TVGN","market":"US","secType":"STK","nameCN":"Tevogen Bio Holdings","latestPrice":7.91,"timestamp":1780084800000,"preClose":8.04,"halted":0,"volume":25772,"hourTrading":{"tag":"盘后","latestPrice":7.91,"preClose":7.91,"latestTime":"17:41 EDT","volume":9,"amount":71.19,"timestamp":1780090861326,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.0161691542288556,"floatShares":1133000,"shares":4164205,"eps":-6.483579,"marketStatus":"Market Closed","change":-0.13,"latestTime":"05-29 16:00:00 EDT","open":7.51,"high":8.0417,"low":7.5,"amount":199118.904784,"amplitude":0.067376,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-6.483579,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1780300800000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":8.04,"preHourTrading":{"tag":"盘前","latestPrice":7.85,"preClose":8.04,"latestTime":"09:29 EDT","volume":527,"amount":4266.755897,"timestamp":1780061341008,"change":-0.19,"changeRate":-0.023632,"amplitude":0.083333},"postHourTrading":{"tag":"盘后","latestPrice":7.91,"preClose":7.91,"latestTime":"17:41 EDT","volume":9,"amount":71.19,"timestamp":1780090861326,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.4038498313053503},"requestUrl":"/m/hq/s/TVGN","defaultTab":"news","newsList":[{"id":"2639690737","title":"Tevogen advances strategic acquisition initiatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2639690737","media":"TIPRANKS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639690737?lang=en_us&edition=fundamental","pubTime":"2026-05-29 01:30","pubTimestamp":1779989406,"startTime":"0","endTime":"0","summary":"Tevogen (TVGN) announced continued progress across its strategic acquisition initiatives intended to complement its existing business and support l...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tevogen-advances-strategic-acquisition-initiatives-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tevogen-advances-strategic-acquisition-initiatives-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TVGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639150697","title":"Tevogen advances talks on strategic acquisitions, including CRO deal under review","url":"https://stock-news.laohu8.com/highlight/detail?id=2639150697","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639150697?lang=en_us&edition=fundamental","pubTime":"2026-05-29 00:30","pubTimestamp":1779985819,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings is pursuing strategic acquisitions, including evaluation of a contract research organization, targeting about $100 million in combined annual revenue.The deals are intended to add a healthcare services arm alongside Tevogen Bio and Tevogen.AI as the group pushes toward financial self-sufficiency.Any transactions remain subject to due diligence, definitive agreements, required approvals, and customary closing conditions.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL1qJlTj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","LU2095319765.USD","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BN0W2T93.GBP","LU2210150020.SGD","BK4585","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014005.SGD","TVGN","NDAQ","BK4588","BK4112","LU0314104364.USD","BK4139","IE00BGHQF748.EUR","SG9999014013.SGD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639697115","title":"Tevogen Advances Strategic Acquisition Initiatives With Potential to Support Approximately $100 Million in Combined Annual Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2639697115","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639697115?lang=en_us&edition=fundamental","pubTime":"2026-05-29 00:30","pubTimestamp":1779985800,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nTUA2CXDJQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGN","BK4139","TVGNW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639971356","title":"Press Release: Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2639971356","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639971356?lang=en_us&edition=fundamental","pubTime":"2026-05-29 00:30","pubTimestamp":1779985800,"startTime":"0","endTime":"0","summary":"WARREN, N.J., May 28, 2026  -- Tevogen   today announced continued progress across its strategic acquisition initiatives intended to complement its existing business and support long-term financial self-sufficiency, which, if consummated, could realize approximately $100 million in combined annual revenue. These initiatives include the Company's previously announced evaluation of a contract research organization , along with additional strategic acquisition opportunities aligned with Tevogen's broader healthcare platform.Tevogen believes these and other strategic acquisition initiatives could support the Company's evolution into a revenue-generating healthcare enterprise comprised of Tevogen Bio, its biotechnology arm; Tevogen.AI, its technology arm; and, subject to completion of proposed transactions, a healthcare services arm that may include management services and contract research operations.Tevogen.AI is designed to transform drug development by accelerating target detection, hel","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4550","TVGN","BK4604","03160","BK4555","BK4139","IXJ","BK4099","BK4585","TM","VHT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637533003","title":"Tevogen Bio Signs LOI to Assess Potential Acquisition of Management Services Organization","url":"https://stock-news.laohu8.com/highlight/detail?id=2637533003","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637533003?lang=en_us&edition=fundamental","pubTime":"2026-05-22 00:40","pubTimestamp":1779381627,"startTime":"0","endTime":"0","summary":"Tevogen Bio (TVGN) said Thursday it signed a nonbinding letter of intent to evaluate a potential transaction with an undisclosed management services organization.Price: 11.57, Change: +1.09, Percent Change: +10.40","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TVGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637449358","title":"Tevogen signs LOI to evaluate acquisition of management services organization","url":"https://stock-news.laohu8.com/highlight/detail?id=2637449358","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637449358?lang=en_us&edition=fundamental","pubTime":"2026-05-22 00:15","pubTimestamp":1779380122,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings entered a signed, non-exclusive, non-binding letter of intent to evaluate a potential acquisition of a management services organization.The deal is positioned to expand Tevogen’s healthcare infrastructure and support a broader push into healthcare services alongside its biotech and AI units.Management said the MSO evaluation, combined with a previously disclosed review of a contract research organization and other acquisition efforts, could support a path toward about $100 million in combined annual revenue if completed.The potential transaction remains subject to due diligence, definitive documentation, required approvals, and customary closing conditions.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL361HH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","IE00BGHQF748.EUR","LU2210150020.SGD","SG9999014021.USD","IE00BN0W2W23.USD","SG9999014013.SGD","BK4585","TVGN","BK4139","LU2210149790.SGD","SG9999014039.USD","IE00BN0W2V16.EUR","BK4588","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","SG9999014005.SGD","IE00BKPKM429.USD","BK4112","LU0314104364.USD","NDAQ","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637358110","title":"Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Management Services Organization","url":"https://stock-news.laohu8.com/highlight/detail?id=2637358110","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637358110?lang=en_us&edition=fundamental","pubTime":"2026-05-22 00:15","pubTimestamp":1779380100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nTUA3C6SDV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGNW","BK4139","TVGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635305512","title":"Tevogen Bio Holdings Q1 EPS $(1.61) Beats $(2.50) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635305512","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635305512?lang=en_us&edition=fundamental","pubTime":"2026-05-16 06:57","pubTimestamp":1778885845,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings (NASDAQ:TVGN) reported quarterly losses of $(1.61) per share which beat the analyst consensus estimate of $(2.50) by 35.6 percent. This is a 50.46 percent increase over losses of $(3.25) per share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52620699/tevogen-bio-holdings-q1-eps-1-61-beats-2-50-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Tevogen Bio Holdings Q1 EPS $(1.61) Beats $(2.50) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635058429","title":"Tevogen Bio Q1 FY26 net loss narrows 47.47% to $5.45 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635058429","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635058429?lang=en_us&edition=fundamental","pubTime":"2026-05-16 05:06","pubTimestamp":1778879183,"startTime":"0","endTime":"0","summary":"Tevogen Bio Holdings posted a net loss of USD 5.45 million for the quarter ended March 31, 2026, narrowing from a net loss of USD 10.37 million a year earlier.Operating loss improved to USD 5.4 million from USD 10.36 million, as total operating expenses fell to USD 5.4 million from USD 10.36 million.General and administrative costs dropped to USD 2.27 million from USD 7.16 million on lower legal and professional fees and stock-based compensation, while research and development spend edged down to USD 3.13 million from USD 3.2 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tevogen Bio Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL9M8Bpv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635859244","title":"Tevogen Bio Holdings Inc trading resumes","url":"https://stock-news.laohu8.com/highlight/detail?id=2635859244","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635859244?lang=en_us&edition=fundamental","pubTime":"2026-05-13 02:07","pubTimestamp":1778609275,"startTime":"0","endTime":"0","summary":"11:50 EDT Tevogen (TVGN) Bio Holdings Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking fin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tevogen-bio-holdings-inc-trading-resumes-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tevogen-bio-holdings-inc-trading-resumes-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TVGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634724568","title":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 11:45 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2634724568","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634724568?lang=en_us&edition=fundamental","pubTime":"2026-05-12 23:45","pubTimestamp":1778600721,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  VOLATILITY TRADING PAUSE AT 11:45 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nAQN2LYPK7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634245507","title":"Tevogen Announces $3 Million Private Investment at $8 per Share, a 14% Premium From Latest Market Close","url":"https://stock-news.laohu8.com/highlight/detail?id=2634245507","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634245507?lang=en_us&edition=fundamental","pubTime":"2026-05-12 23:45","pubTimestamp":1778600720,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nFWN41P1EN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TVGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634245503","title":"Tevogen Bio Holdings Inc - Announces $3 Mln Pipe Financing With the Patel Family, Llp","url":"https://stock-news.laohu8.com/highlight/detail?id=2634245503","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634245503?lang=en_us&edition=fundamental","pubTime":"2026-05-12 23:45","pubTimestamp":1778600720,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nFWN41P1EN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGN","BK4139","TVGNW"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634924569","title":"Press Release: Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close","url":"https://stock-news.laohu8.com/highlight/detail?id=2634924569","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634924569?lang=en_us&edition=fundamental","pubTime":"2026-05-12 23:45","pubTimestamp":1778600700,"startTime":"0","endTime":"0","summary":"WARREN, N.J., May 12, 2026  -- Tevogen   today announced that it has entered into a securities purchase agreement for a private investment in public equity  financing with existing investor The Patel Family, LLP for gross proceeds of $3 million. The Company intends to use the proceeds from the PIPE financing to support ongoing operations, advance strategic growth initiatives, and for general corporate purposes.Pursuant to the terms of the securities purchase agreement, Tevogen will issue 375,000 prefunded warrants each exercisable for the purchase of one share of the Company's common stock. The PIPE financing was priced at $8.00 per prefunded warrant, which represents a 14% premium to the closing price of the Company's stock on May 11, 2026. The PIPE financing is expected to close on or about May 13, 2026.\"Having The Patel Family, LLP continue to support Tevogen reflects a shared belief in both our mission and our long-term vision for building a more accessible and sustainable healthca","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","03160","BK4585","TVGN","BK4139","TM","BK4099","BK4604","BK4555"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634245331","title":"Tevogen Bio prices USD 3 million PIPE at USD 8 per share premium","url":"https://stock-news.laohu8.com/highlight/detail?id=2634245331","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634245331?lang=en_us&edition=fundamental","pubTime":"2026-05-12 23:40","pubTimestamp":1778600453,"startTime":"0","endTime":"0","summary":"Tevogen Bio entered USD 3 million PIPE with existing investor The Patel Family, LLP, priced at USD 8 per prefunded warrant.Deal calls for issuance of 375,000 prefunded warrants, each exercisable for one common share, representing a 14% premium to May 11 close.Securities are unregistered; company plans to file a resale registration statement covering shares issuable on exercise.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tevogen Bio Holdings Inc. published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL5DHdYc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630031535","title":"Tevogen says PredicTcell training nears completion, precision improves about 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630031535","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630031535?lang=en_us&edition=fundamental","pubTime":"2026-04-27 23:50","pubTimestamp":1777305026,"startTime":"0","endTime":"0","summary":"Tevogen reported PredicTcell, machine-learning model for identifying immunologically active peptides, is nearing completion of its training phase.Model training used one of industry’s largest curated peptide datasets; feature expansion exceeded 180 parameters.Tevogen cited about 10% improvement in precision from latest feature expansion.Company began evaluating potential co-development partnerships to broaden use of platform aimed at improving target identification in drug development.Tevogen built initial internal application portal to serve PredicTcell in scalable environment, positioning platform for potential commercialization.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDL1T6C55:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","SG9999014013.SGD","SG9999014039.USD","BK4112","LU0314104364.USD","IE00BN0W2W23.USD","LU2210150020.SGD","BK4588","LU2095319765.USD","BK4585","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU2210149790.SGD","BK4139","TVGN","SG9999014005.SGD","IE00B64PRP62.GBP","NDAQ","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629075847","title":"Tevogen Bio gets Nasdaq notice for failing $50 million market value requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2629075847","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629075847?lang=en_us&edition=fundamental","pubTime":"2026-04-23 05:16","pubTimestamp":1776892572,"startTime":"0","endTime":"0","summary":"Nasdaq warned Tevogen Bio failed to meet continued-listing thresholds tied to market value.Letter dated April 16, 2026 cited market value of listed securities below USD 50 million for 30 consecutive business days.Second notice dated April 17, 2026 cited market value of publicly held shares below USD 15 million for 30 consecutive business days.Nasdaq set compliance deadlines of Oct. 13, 2026 for MVLS requirement, Oct. 14, 2026 for MVPHS requirement.Tevogen Bio may pursue steps to regain compliance, including evaluating a transfer to Nasdaq Capital Market.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tevogen Bio Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analy","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL5ncV59:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624152553","title":"Tevogen Bio FY25 net loss widens to $26.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2624152553","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624152553?lang=en_us&edition=fundamental","pubTime":"2026-04-01 05:17","pubTimestamp":1774991859,"startTime":"0","endTime":"0","summary":"Tevogen Bio posted a net loss of $26.3 million for fiscal 2025.Operating loss narrowed to $26.1 million from $53.6 million a year earlier.Research and development expense fell to $11.1 million, due mainly to lower non-cash stock-based compensation.Management said cash resources should fund operations for at least 12 months from issuance of the financial statements.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tevogen Bio Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 31, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL5nFlRB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TVGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622898459","title":"BRIEF-Tevogen Advances Strategic CRO Evaluation To Expand Clinical Research Delivery Capabilities And Drive Revenue Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2622898459","media":"Reuters","labels":["corporation","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622898459?lang=en_us&edition=fundamental","pubTime":"2026-03-27 02:12","pubTimestamp":1774548761,"startTime":"0","endTime":"0","summary":"BRIEF-Tevogen Advances Strategic CRO Evaluation To Expand Clinical Research Delivery Capabilities And Drive Revenue GrowthMarch 26 (Reuters) - Tevogen Bio Holdings Inc TVGN.O:TEVOGEN ADVANCES STRATEGI","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nFWN40E14J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TVGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622867698","title":"Tevogen Bio Holdings: Opportunity Expected to Contribute More Than $20 Mln in Annual Revenue While Supporting Double-Digit Growth Beginning Next Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2622867698","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622867698?lang=en_us&edition=fundamental","pubTime":"2026-03-27 00:46","pubTimestamp":1774543580,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nFWN40E14J:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TVGN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://semperparatusspac.com","stockEarnings":[{"period":"1week","weight":-0.1769},{"period":"1month","weight":0.2321},{"period":"3month","weight":-0.4012},{"period":"6month","weight":-0.6414},{"period":"1year","weight":-0.8819},{"period":"ytd","weight":-0.5222}],"compareEarnings":[{"period":"1week","weight":0.0145},{"period":"1month","weight":0.0631},{"period":"3month","weight":0.1028},{"period":"6month","weight":0.107},{"period":"1year","weight":0.2821},{"period":"ytd","weight":0.1093}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.040664},{"month":2,"riseRate":0.6,"avgChangeRate":0.049009},{"month":3,"riseRate":0.4,"avgChangeRate":-0.264435},{"month":4,"riseRate":0.6,"avgChangeRate":-0.057531},{"month":5,"riseRate":0.4,"avgChangeRate":0.045094},{"month":6,"riseRate":0.25,"avgChangeRate":-0.034979},{"month":7,"riseRate":0.5,"avgChangeRate":-0.078575},{"month":8,"riseRate":0.5,"avgChangeRate":-0.064152},{"month":9,"riseRate":0.5,"avgChangeRate":-0.105281},{"month":10,"riseRate":0.75,"avgChangeRate":1.418967},{"month":11,"riseRate":0.5,"avgChangeRate":-0.189646},{"month":12,"riseRate":0.5,"avgChangeRate":-0.111833}],"exchange":"NASDAQ","name":"Tevogen Bio Holdings","nameEN":"Tevogen Bio Holdings"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tevogen Bio Holdings(TVGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tevogen Bio Holdings(TVGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tevogen Bio Holdings,TVGN,Tevogen Bio Holdings股票,Tevogen Bio Holdings股票老虎,Tevogen Bio Holdings股票老虎国际,Tevogen Bio Holdings行情,Tevogen Bio Holdings股票行情,Tevogen Bio Holdings股价,Tevogen Bio Holdings股市,Tevogen Bio Holdings股票价格,Tevogen Bio Holdings股票交易,Tevogen Bio Holdings股票购买,Tevogen Bio Holdings股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tevogen Bio Holdings(TVGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tevogen Bio Holdings(TVGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}